In conclusion, the findings of our decision analysis suggest that
topical application of mupirocin at the catheter exit site during the
first 12 months of PD appears to be a cost-effective preventive
measure against gram-positive infections from the perspective of
health care providers in Hong Kong. The cost-effectiveness of this
mupirocin regimen is affected by the level of risk reduction in infections
and subject to resistance against mupirocin. Prospective
clinical trials are warranted to determine the long-term clinical
impact of daily application of mupirocin in preventing PD-related
gram-positive infections.